Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong’s Insilico Medicine: Report
Eli Lilly will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine , which uses artificial intelligence for drug discovery, the Financial Times reported on Sunday.
Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.
Reuters could not immediately verify the report.
